Nanjing Leads Biolabs Co., Ltd. is a clinical-stage R&D biotech company founded in Nanjing by a senior antibody therapy research and development team from the United States. Our company is committed to researching and developing novel antibody-based therapeutics in oncology and immunology to address global unmet patient needs. On our monoclonal antibody and bispecific antibody development technology platform, we already have a robust R&D pipeline of more than ten innovative cancer immunotherapy antibody projects. The company will continue to innovate in order to provide patients with new drugs that are safe, effective, accessible, and affordable in order to meet unmet medical needs.